• Je něco špatně v tomto záznamu ?

Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score

K. Kolostova, M. Broul, J. Schraml, M. Cegan, R. Matkowski, M. Fiutowski, V. Bobek,

. 2014 ; 34 (7) : 3641-6.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074137

The most promising near-term application of circulating tumor cells (CTCs) monitoring relates to the development of targeted cancer therapies, and the need to tailor such treatments to individual tumor characteristics. A high number of new innovative technologies to improve methods for detecting CTCs, with extraordinarily high sensitivity, have recently been presented. The identification and characterization of CTCs require extremely sensitive and specific methods that are able to isolate CTCs with the possibility of cultivation and downstream analysis of in vitro culture of separated CTCs. In this original research paper, we demonstrate that it is possible to isolate human CTCs from a patient with prostate cancer, with subsequent cultivation and proliferation in vitro. We show that the use of a filtration device implemented by MetaCell® can fulfil all the requirements mentioned above. Fifty-five patients with localized prostate cancer have so far been enrolled into the study. CTCs were detected in the blood samples of 28 (52%) out of the 55 patients. We report successful isolation of CTCs from patients with prostate cancer, capturing cells with a proliferative capacity in 18 (64.3%) out of the 28 CTC-positive patients. Direct correlation with Gleason score and T stage was not proven. The cells, captured by a size-based filtration approach, remain in a good state, unaffected by any antibodies or lysing solutions. During the filtration process, no interactions occurred between antibodies and antigens on the surface of CTCs. This biological interaction is specific for immunomagnetic methods. The MetaCell device provides the possibility of reaching virgin CTCs suitable for subsequent cultivation or single-cell analysis. This aspect will have an important impact on the future design of clinical trials testing new drugs against targets expressed on metastatic cancer cells. In addition to measurement of CTC counts, future trials with targeted therapies should also include the assessment of the specific therapeutic target on CTCs.

000      
00000naa a2200000 a 4500
001      
bmc14074137
003      
CZ-PrNML
005      
20160610122626.0
007      
ta
008      
141006s2014 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)24982381
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kolostova, Katarina $u Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
245    10
$a Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score / $c K. Kolostova, M. Broul, J. Schraml, M. Cegan, R. Matkowski, M. Fiutowski, V. Bobek,
520    9_
$a The most promising near-term application of circulating tumor cells (CTCs) monitoring relates to the development of targeted cancer therapies, and the need to tailor such treatments to individual tumor characteristics. A high number of new innovative technologies to improve methods for detecting CTCs, with extraordinarily high sensitivity, have recently been presented. The identification and characterization of CTCs require extremely sensitive and specific methods that are able to isolate CTCs with the possibility of cultivation and downstream analysis of in vitro culture of separated CTCs. In this original research paper, we demonstrate that it is possible to isolate human CTCs from a patient with prostate cancer, with subsequent cultivation and proliferation in vitro. We show that the use of a filtration device implemented by MetaCell® can fulfil all the requirements mentioned above. Fifty-five patients with localized prostate cancer have so far been enrolled into the study. CTCs were detected in the blood samples of 28 (52%) out of the 55 patients. We report successful isolation of CTCs from patients with prostate cancer, capturing cells with a proliferative capacity in 18 (64.3%) out of the 28 CTC-positive patients. Direct correlation with Gleason score and T stage was not proven. The cells, captured by a size-based filtration approach, remain in a good state, unaffected by any antibodies or lysing solutions. During the filtration process, no interactions occurred between antibodies and antigens on the surface of CTCs. This biological interaction is specific for immunomagnetic methods. The MetaCell device provides the possibility of reaching virgin CTCs suitable for subsequent cultivation or single-cell analysis. This aspect will have an important impact on the future design of clinical trials testing new drugs against targets expressed on metastatic cancer cells. In addition to measurement of CTC counts, future trials with targeted therapies should also include the assessment of the specific therapeutic target on CTCs.
650    _2
$a senioři $7 D000368
650    _2
$a kohortové studie $7 D015331
650    _2
$a cytologické techniky $x metody $7 D003584
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádorové cirkulující buňky $x patologie $7 D009360
650    _2
$a nádory prostaty $x krev $x patologie $7 D011471
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Broul, Marek $u Clinic of Urology and Robotic Surgery, Masaryk's Hospital, Usti nad Labem, Czech Republic. $7 xx0117935
700    1_
$a Schraml, Jan $u Clinic of Urology and Robotic Surgery, Masaryk's Hospital, Usti nad Labem, Czech Republic.
700    1_
$a Cegan, Martin $u Department of Pathology, Masaryk's Hospital, Usti nad Labem, Czech Republic.
700    1_
$a Matkowski, Rafal $u Division of Oncology and Surgical Oncology, Wroclaw Medical University, Wroclaw, Poland Department of Surgical Oncology, Lower Silesian Oncology Centre, Wroclaw, Poland.
700    1_
$a Fiutowski, Marek $u Department of Urology, Regional Specialist Hospital, Wroclaw, Poland.
700    1_
$a Bobek, Vladimir $u Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland vbobek@centrum.cz.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 34, č. 7 (2014), s. 3641-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24982381 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20160610122754 $b ABA008
999    __
$a ok $b bmc $g 1042020 $s 873049
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 34 $c 7 $d 3641-6 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Možnosti archivace